Sage Therapeutics, a Cambridge-based drug developer, is being acquired by Supernus Pharmaceuticals in a deal worth up to $795 million.
Why it matters: Supernus beat rival bidder Biogen for Sage, despite a long-term partnership between Biogen and Sage to co-develop the postpartum depression medication Zurzuvae.
